2 reports

  • 03/09/2016: Probiodrug PGLU-ABETA Approaches Being Presented At 14Th Aat Symposium On Advances In Alzheimer Therapy
  • 03/09/2016: Probiodrug PGLU-ABETA Approaches Being Presented At 14Th Aat Symposium On Advances In Alzheimer Therapy

Inge Lues, chief development officer of Probiodrug, said, " The results of this comprehensive analysis should give us further insights into the relevance of pGlu Abeta and pGlu Abeta-containing oligomers in the pathology of AD.

  • Pathology
  • Pharmaceutical
  • Austria
  • United States
  • Probiodrug AG
  • Probiodrug AG - Recent Pipeline Updates, 2015
  • Licensing and Collaboration

This may contribute to the formation of several amyloid-related plaque forming peptides, contributing to Alzheimer' s disease pathology.

  • Pathology
  • United States
  • Litigation And Patent
  • Product Initiative
  • Probiodrug AG